Takeda: FDA Accepts NDA Resubmission for Short-Term Treatment of Eosinophilic Esophagitis

Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review its New Drug Application (NDA) resubmission for TAK-721 (budesonide oral suspension) which is being investigated for the short-term treatment of eosinophilic esophagitis (EoE), a chronic inflammatory disease that can cause damage to the esophagus.¹ The resubmission is intended to address previous FDA feedback to the Company’s original NDA submission.

https://www.biospace.com/article/releases/takeda-announces-fda-acceptance-of-nda-resubmission-of-tak-721-budesonide-oral-suspension-for-the-short-term-treatment-of-eosinophilic-esophagitis-eoe-/